The Viral Hemorrhagic Fever Immunotherapeutic Consortium, or VIC, was established in 2014 to develop life-saving antibody therapeutics against some of the world’s deadliest viruses. The VIC represents a field-wide collaboration in which all of the leading laboratories, from over 15 institutions, have united to develop the most efficacious antibody cocktail possible against Ebola virus. This collaborative effort allows each laboratory to contribute their strengths in analytical techniques towards the identification, characterization, and validation of antibodies against the filoviridae family. From isolating novel antibodies against Ebola and testing them in vivo, to the structural analysis of the molecular mechanism for Ebola neutralization, VIC scientists each contribute unique insights towards the overall characterization of each antibody. The consortium is funded through a National Institute of Health National Institute of Allergy and Infectious Diseases Centers for Excellence in Translational Research program grant.